AU2002343556A1 - Use of phosphonate nucleotide analogue for treating hepatitis b virus infections - Google Patents

Use of phosphonate nucleotide analogue for treating hepatitis b virus infections

Info

Publication number
AU2002343556A1
AU2002343556A1 AU2002343556A AU2002343556A AU2002343556A1 AU 2002343556 A1 AU2002343556 A1 AU 2002343556A1 AU 2002343556 A AU2002343556 A AU 2002343556A AU 2002343556 A AU2002343556 A AU 2002343556A AU 2002343556 A1 AU2002343556 A1 AU 2002343556A1
Authority
AU
Australia
Prior art keywords
nucleotide analogue
virus infections
treating hepatitis
phosphonate nucleotide
phosphonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002343556A
Inventor
Stephen Douglas Wise
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002343556A1 publication Critical patent/AU2002343556A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2002343556A 2001-12-07 2002-11-15 Use of phosphonate nucleotide analogue for treating hepatitis b virus infections Abandoned AU2002343556A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33824201P 2001-12-07 2001-12-07
US60/338,242 2001-12-07
US37201302P 2002-04-11 2002-04-11
US60/372,013 2002-04-11
US38112302P 2002-05-16 2002-05-16
US60/381,123 2002-05-16
PCT/US2002/033641 WO2003050129A1 (en) 2001-12-07 2002-11-15 Use of phosphonate nucleotide analogue for treating hepatitis b virus infections

Publications (1)

Publication Number Publication Date
AU2002343556A1 true AU2002343556A1 (en) 2003-06-23

Family

ID=27407255

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002343556A Abandoned AU2002343556A1 (en) 2001-12-07 2002-11-15 Use of phosphonate nucleotide analogue for treating hepatitis b virus infections

Country Status (5)

Country Link
JP (1) JP2005511749A (en)
KR (1) KR20050044587A (en)
CN (1) CN1617877A (en)
AU (1) AU2002343556A1 (en)
WO (1) WO2003050129A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121316A1 (en) 2002-04-26 2004-06-24 Gilead Sciences, Inc. Method and compositions for identifying anti-HIV therapeutic compounds
AU2003280799A1 (en) * 2002-11-15 2004-06-15 Mitsubishi Pharma Corporation Medicinal composition
SG162617A1 (en) * 2002-12-09 2010-07-29 Hudson Technologies Inc Method and apparatus for optimizing refrigeration systems
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
EA200501676A1 (en) 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. PHOSPHONATE-CONTAINING KINASE INHIBITORS (OPTIONS), METHOD FOR THEIR RECEIVING, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM ON THEIR BASIS AND METHOD FOR INHIBING KINASE IN MOLOPYTIC TREATMENT THEM
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
JP2007508843A (en) 2003-10-24 2007-04-12 ギリアード サイエンシーズ， インコーポレイテッド Methods and compositions for the identification of therapeutic compounds
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
JP2007515495A (en) 2003-12-22 2007-06-14 ギリアード サイエンシーズ， インコーポレイテッド 4'-substituted carbovir and abacavir derivatives and related compounds having HIV and HCV antiviral activity
PT2258376T (en) 2004-07-27 2019-05-31 Gilead Sciences Inc Phosphonate analogs of hiv inhibitor compounds
WO2006066074A2 (en) 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
WO2007014491A1 (en) * 2005-08-03 2007-02-08 Beijing Fu Kang Ren Bio-Pharm Tech.Co.Ltd. Acyclic nucleotide phosphonates and their use in antiviral agents
CN102089318B (en) 2008-07-08 2014-05-21 吉里德科学公司 Salts of HIV inhibitor compounds
SG10201800188SA (en) 2013-03-15 2018-02-27 Univ California Acyclic nucleoside phosphonate diesters
JP6708329B2 (en) 2014-09-15 2020-06-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Nucleotide analogues
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
ES2969496T3 (en) 2017-08-01 2024-05-20 Gilead Sciences Inc Crystalline forms of ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl Ethyl (phenoxy)phosphoryl)-L-alaninate to treat viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126601A1 (en) * 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
CA2224710A1 (en) * 1995-06-15 1997-01-03 Naoko Inoue Phosphonate nucleotide derivatives
TW369536B (en) * 1996-01-18 1999-09-11 Mitsubishi Chem Corp Phosphonate nucleotide compounds
CN1085673C (en) * 1996-08-13 2002-05-29 三菱化学株式会社 Phosphonate nucleotide compounds

Also Published As

Publication number Publication date
JP2005511749A (en) 2005-04-28
CN1617877A (en) 2005-05-18
WO2003050129A1 (en) 2003-06-19
KR20050044587A (en) 2005-05-12

Similar Documents

Publication Publication Date Title
AU2002343556A1 (en) Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
IL164729A0 (en) Nucleoside derivatives for treating hepatitis c virus infection
EP1572097A4 (en) Nucleoside derivatives for treating hepatitis c virus infection
AU2003249977A1 (en) Imidazole compounds for the treatment of hepatitis c virus infections
SI1404347T1 (en) 4'-substituded nucleosides for the treatment of diseases mediated by the hepatitis c virus
AU2002364730A1 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
AU2002330154A1 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
AU2158000A (en) Treatment of hepatitis c virus infections with interleukin-10
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
AU2003216523A1 (en) Treatment of pre-core hepatitis b virus mutant infections
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
IL157251A0 (en) Hepatitis b virus treatment
AU2003294757A1 (en) Formulations useful against hepatitis c virus infections
NO20022816L (en) Treatment of viral infections using levovirin
AU2001236938A1 (en) Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
AU2002324753A1 (en) Composition and method for treating viral infection
AU2002359327A1 (en) Method of treating viral infections
AU3858600A (en) Glucamine compounds for treating hepatitis virus infections
AU2001292947A1 (en) Methods for inhibition of viral infection
NO20032769L (en) Combination method for the treatment of viral infections
AU2003237088A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
AU2001234596A1 (en) Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
AU2001288870A1 (en) Antiviral compounds and method of treating viral infections

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase